



ARTICLE

Clinical Study

Impact of breast cancer molecular subtypes on the incidence, kinetics and prognosis of central nervous system metastases in a large multicentre real-life cohort

Amélie Darlix¹, Guillaume Louvel², Julien Fraisse³, William Jacot^{1,4}, Etienne Brain⁵, Marc Debled⁶, Marie Ange Mouret-Reynier⁷, Anthony Goncalves⁸, Florence Dalenc⁹, Suzette Delaloge¹⁰, Mario Camponi¹¹, Paule Augereau¹², Jean Marc Ferrero¹³, Christelle Levy¹⁴, Jean-David Fumet¹⁵, Isabelle Lecouillard¹⁶, Paul Cottu⁵, Thierry Petit¹⁷, Lionel Uwer¹⁸, Christelle Jouannaud¹⁹, Marianne Leheurteur²⁰, Véronique Dieras¹⁶, Mathieu Robain²¹, Michaël Chevrot²¹, David Pasquier²² and Thomas Bachelot²³

BACKGROUND: Metastatic breast cancer (MBC) behaviour differs depending on hormone receptors (HR) and human epidermal growth factor receptor (HER2) statuses.

METHODS: The kinetics of central nervous system (CNS) metastases (CNS metastasis-free survival, CNSM-FS) and subsequent patient's prognosis (overall survival, OS) according to the molecular subtype were retrospectively assessed in 16703 MBC patients of the ESME nationwide multicentre MBC database (Kaplan–Meier method).

RESULTS: CNS metastases occurred in 4118 patients (24.6%) (7.2% at MBC diagnosis and 17.5% later during follow-up). Tumours were HER2–/HR+ (45.3%), HER2+/HR+ (14.5%), HER2+/HR– (14.9%) and triple negative (25.4%). Median age at CNS metastasis diagnosis was 58.1 years (range: 22.8–92.0). The median CNSM-FS was 10.8 months (95% CI: 16.5–17.9) among patients who developed CNS metastases. Molecular subtype was independently associated with CNSM-FS (HR = 3.45, 95% CI: 3.18–3.75, triple-negative and HER2–/HR+ tumours). After a 30-month follow-up, median OS after CNS metastasis diagnosis was 7.9 months (95% CI: 7.2–8.4). OS was independently associated with subtypes: median OS was 18.9 months (HR = 0.57, 95% CI: 0.50–0.64) for HER2+/HR+, 13.1 months (HR = 0.72, 95% CI: 0.65–0.81) for HER2+/HR–, 4.4 months (HR = 1.55, 95% CI: 1.42–1.69) for triple-negative and 7.1 months for HER2–/HR+ patients ($p < 0.0001$).

CONCLUSIONS: Tumour molecular subtypes strongly impact incidence, kinetics and prognosis of CNS metastases in MBC patients.

CLINICAL TRIAL REGISTRATION: NCT03275311.

British Journal of Cancer (2019) 121:991–1000; <https://doi.org/10.1038/s41416-019-0619-y>

BACKGROUND

Breast cancer is the second most frequent cancer affecting women, and the second most common cause of central nervous system (CNS) metastases, i.e., brain metastases (BM) or leptomeningeal metastases (LM). In total, 30–50% of patients with metastatic breast

cancer (MBC) will develop BM in the course of their disease.¹ The proportion of patients with BM among MBC patients is even higher when considering asymptomatic BM, as suggested in studies evaluating screening strategies^{2,3} or autopsy studies.⁴ The incidence of both BM^{5,6} and LM⁷ has increased. Reasons are longer survival of

¹Department of Medical Oncology, Institut du Cancer de Montpellier (ICM), University of Montpellier, 208 Rue des Apothicaires, 34298 Montpellier, France; ²Department of Radiation Therapy, Gustave Roussy, 114 Rue Edouard Vaillant, 94800 Villejuif, France; ³Biometrics Unit, Institut du Cancer de Montpellier (ICM), University of Montpellier, 208 Rue des Apothicaires, 34298 Montpellier, France; ⁴Institut de Recherche en Cancérologie de Montpellier (IRCM), INSERM U1194, Institut du Cancer de Montpellier, University of Montpellier 208 Rue des Apothicaires, 34298 Montpellier, France; ⁵Department of Medical Oncology, Institut Curie, 26 Rue d'Ulm, 75005 Paris & Saint-Cloud, France; ⁶Department of Medical Oncology, Institut Bergonié, 229 Cours de l'Argonne, 33000 Bordeaux, France; ⁷Department of Medical Oncology, Centre Jean Perrin, 58 Rue Montalembert, 63011 Clermont Ferrand, France; ⁸Department of Medical Oncology, Institut Paoli-Calmettes, 232 Boulevard de Sainte-Marguerite, 13009 Marseille, France; ⁹Department of Medical Oncology, Institut Claudius Regaud – IUCT Oncopole, 1 Avenue Irène-Joliot-Curie, 31059 Toulouse, France; ¹⁰Department of Cancer Medicine, Gustave Roussy, 114 Rue Edouard-Vaillant, 94800 Villejuif, France; ¹¹Department of Medical Oncology, Institut de Cancérologie de l'Ouest Centre René Gauducheau, Boulevard Jacques Monod, 44805 Saint Herblain, France; ¹²Department of Medical Oncology, Institut de Cancérologie de l'Ouest, 15 rue André Boquel, 49055 Angers, France; ¹³Department of Medical Oncology, Centre Antoine Lacassagne, 33 Avenue de valambrose, 06189 Nice, France; ¹⁴Department of Medical Oncology, Centre François Baclesse, 3 Avenue du Général Harris, 14000 Caen, France; ¹⁵Department of Medical Oncology, Centre Georges François Leclerc, 1 rue Professeur Marion, 21079 Dijon, France; ¹⁶Department of Radiation Oncology, Centre Eugène Marquis, Avenue de la Bataille Flandres-Dunkerque, 35000 Rennes, France; ¹⁷Department of Medical Oncology, Centre Paul Strauss, 3 Rue de la Porte de l'Hôpital, 67000 Strasbourg, France; ¹⁸Medical Oncology Department, Institut de Cancérologie de Lorraine, 6 Avenue de Bourgogne, 54519 Vandœuvre-lès-Nancy, France; ¹⁹Department of Medical Oncology, Institut de Cancérologie Jean-Godinot, 1 Rue du Général Koenig, 51100 Reims, France; ²⁰Department of Medical Oncology, Centre Henri Becquerel, Rue d'Amiens, 76000 Rouen, France; ²¹Department of Research and Development, Unicancer, 101 Rue de Tolbiac, 75654 Paris, France; ²²Academic Department of Radiation Oncology, Centre Oscar Lambret, 3 Rue Frédéric Combemale, 59000 Lille, France and ²³Department of Medical Oncology, Centre Léon Bérard, 28 Promenade Léa et Napoléon Bullukian, 69008 Lyon, France

Correspondence: Amélie Darlix (amelie.darlix@icm.unicancer.fr)

Received: 27 June 2019 Revised: 10 October 2019 Accepted: 17 October 2019

Published online: 13 November 2019

MBC patients,⁸ the inability of some drugs to cross the blood–brain barrier, an increased control of the systemic disease by human epidermal growth factor receptor 2 (HER2) targeted therapies⁵ or use of more sensitive diagnosis techniques for CNS metastases.

Identifying patients at risk of developing CNS metastases seems crucial. As asymptomatic CNS metastases are frequent, patients at high risk could benefit from screening strategies in order to improve outcomes by allowing, for example, localised BM treatments in a higher proportion of patients.² Indeed, surgery and radiosurgery are yet the only locoregional treatments with a significant positive impact on survival in patients with BM.^{9,10} Risk factors for BM occurrence include younger age at the time of the breast cancer diagnosis,¹¹ shorter disease-free survival¹² and the presence of lung metastases.^{11–13} The biological characteristics of the initial tumour also have an effect on CNS metastasis occurrence.^{6,11,14–16} Hormone receptor (HR) negativity^{12,13,17–19} and HER2 positivity^{11,20} are indeed important risk factors for BM occurrence. Interestingly, differences regarding the time interval to CNS metastasis occurrence according to the breast cancer subtype have been described, with a shorter time interval from BC diagnosis^{19,21} or MBC¹² to CNS metastasis occurrence for patients with HR-negative²² or triple-negative tumours.^{12,19,21} However, these studies were either mono- or bicentric and included a limited number of patients.

Prognosis of patients with CNS metastases is poor, with a median overall survival (OS) ranging from 4 to 25 months for BM^{23,24} and of <6 months in most published series for LM.^{25,26} It depends on various factors, including the patient's age^{19,27} and performance status, the time interval between the diagnosis of cancer and that of CNS metastases,²⁷ the number of BM,¹⁹ the treatment¹⁹ (localised treatment vs. no localised treatment) and the control of the extracranial disease.²⁸ The tumour biology status also seems to impact outcome, with prolonged survival after BM diagnosis in HER2-positive tumours^{19,22} or poorer survival after LM diagnosis in patients with HR- or triple-negative tumours.^{25,27}

The objectives of this study were to provide new data regarding the risk and kinetics of CNS metastasis occurrence during the course of MBC, to identify clinical and biological features associated with a high risk of developing CNS metastases or a shorter time to CNS metastases and to evaluate the patients' prognosis.

PATIENTS AND METHODS

Study design

We performed a retrospective analysis of the 16,703 MBC patients included in the French *Epidemiological Strategy and Medical Economics* (ESME) research programme, to which 18 French specialised cancer centres are participating. The ESME MBC database (NCT03275311) was established, and is managed by R&D UNICANCER.^{29,30} The database included all adult patients treated in first line for an MBC between January 2008 and December 2014, in one of the participating centres.

Objectives of the study

The primary objective of this study was to evaluate the time interval between MBC diagnosis (stage IV disease) and the occurrence of CNS metastases (CNS metastasis-free survival, CNSM-FS), according to the breast cancer immunohistochemical subtype. The secondary objectives were to evaluate the time interval between the first breast cancer diagnosis and CNS metastases and OS, and to describe progression-free survival (PFS) and CNS–PFS after CNS metastases.

Selection criteria

For this study, two populations were identified. The overall population included all ESME MBC database patients. Two patients were excluded from analysis due to inconsistencies within the data (population 1). CNSM-FS was evaluated in this population. To evaluate the prognostics of patients after the occurrence of CNS

metastases, population 2 included patients from the ESME MBC database diagnosed with CNS metastases at MBC diagnosis or later during the course of MBC. Of note, as the ESME MBC database did not differentiate intraparenchymal BM from LM, both metastatic sites were merged for the analyses.

Data collected

For all patients, data were extracted from the ESME MBC database. Oestrogen receptors (ER), progesterone receptors (PR) and HER2 statuses were described both at the time of the primary tumour diagnosis and at the time of MBC diagnosis, as some phenotypic changes can be observed between the primary tumour and metastatic recurrence. The HER2 and HR statuses used for statistical analyses were derived from existing results about metastatic tissue sampling, when available, or, if not available, from the last sampling of early breast cancer.

Statistical considerations

Categorical variables were reported: the number of unavailable data, number and percentage for each variable modality. For continuous variables, the number of missing data, mean, standard deviation, median and range values were computed. All variables were compared by using the Pearson's χ^2 test or Student's *t* test, when appropriate. The incidence and prevalence of CNS metastases were calculated in the whole population and in subgroups according to the HR and HER2 statuses. The incidence rate of CNS metastases was defined as the number of patients diagnosed with CNS metastases per 100 person-years, i.e., among 100 patients from population 1 followed for 1 year.

The CNSM-FS was defined as the time interval between the date of MBC diagnosis and the date of CNS metastasis diagnosis. Patients with CNS metastases occurring after the closing date of study analysis (January 15th, 2016), lost to follow-up or dead without CNS metastases were censored at the closing date of analysis. The CNSM-FS was estimated by using the Kaplan–Meier method, presented as median with its 95% confidence interval (95% CI), and survival rates in percentages, with 95% CIs. Survival estimations were compared with the log-rank test. To evaluate the prognostics of patients with CNS metastases, the time between CNS metastasis occurrence and death from any cause (OS), systemic or CNS progression (PFS) and CNS progression (CNS–PFS) were estimated by using the same methods, with adjustment on the major prognostic factors. Patients alive without events were censored at the closing date of study analysis. To investigate prognostic factors, a multivariate analysis was performed by using the Cox's proportional hazards regression model with a backward procedure. Hazard ratios with their 95% CIs were calculated to display risk changes. All *p*-values reported were two-sided, and the significance level was set at 5% ($p < 0.05$). Statistical analysis was performed by using the SAS[®] software (version 9.4).

RESULTS

Population analysed

A total of 16,703 MBC patients were included in the ESME MBC database (Fig. 1). After exclusion of two patients due to inconsistent data, 16,701 patients were included in the present analysis (population 1). Among them, 4800 had de novo metastatic breast cancer and 11,901 relapsed MBC. After a median follow-up of 42.8 months (95% CI: 42.0–43.7), 4118 patients of population 1 (24.6%) developed CNS metastases. In total, 4033 of them were included in population 2 (85 excluded since diagnosis after 15/01/2016). The characteristics of the two populations of the study are described in Table 1.

Characteristics of CNS metastases

With a median follow-up of 42.8 months, CNS metastases occurred in 24.6% of all patients from population 1. The incidence rate of




Fig. 1 Study flowchart: patients included in the study

CNS metastases (number of patients diagnosed with CNS metastases per 100 person-years, i.e., among 100 patients from population 1 followed for 1 year) was 21.8% in HER2-positive tumours (compared with 11.1% in HER2-negative tumours), 32.5% in HR-negative tumours (compared with 9.2% in HR-positive tumours) and 32.7% in triple-negative tumours, respectively.

The cumulated incidence rate of CNS metastases at 12 months (after MBC diagnosis) was 8.3% (95% CI: 7.8–8.9), 16.8% (95% CI: 15.0–18.8), 32.4% (95% CI: 29.7–35.4) and 29.8% (95% CI: 27.9–31.8) in patients with HER2–/HR+, HER2+/HR+, HER2+/HR– and triple-negative tumours, respectively. At 24 months, it was 14.4% (95% CI: 13.6–15.2), 29.2% (95% CI: 26.8–31.8), 49.0% (95% CI: 45.7–52.5) and 44.8% (95% CI: 42.3–47.3) in patients with HER2–/HR+, HER2+/HR+, HER2+/HR– and triple-negative tumours (Supplementary Table 1). The incidence continued increasing for all tumour subtypes, with no sign of flattening of the incidence over time (cumulated incidence rates up to 36.9%, 53.5%, 72.6% and 71.3% in patients with HER2–/HR+, HER2+:HR+, HER2+/HR– and triple-negative tumours).

The incidence rate of CNS metastases was 13.2% in patients with de novo MBC, and 10.9% in patients with relapse MBC. Among the 4118 patients diagnosed with CNS metastases, 1200 (29.1%) presented with CNS metastases at the time of the initial diagnosis of metastatic disease (isolated CNS metastases in 43.1% of cases). In the overall population, the proportion of patients diagnosed with CNS metastases at metastatic disease diagnosis was 7.2% (4.3%, 9.2%, 17.0% and 13.1% in patients with HER2–/HR+, HER2+/HR+, HER2+/HR– and triple-negative tumours, respectively).

In total, 85 patients from Population 1 were diagnosed with CNS metastases after January 15, 2016 and were excluded from Population 2, which thus included a total of 4033 patients. In this population, the median age at CNS metastases diagnosis was 58.1 years overall; it was 54.1 years for triple-negative patients and 59.9 years for HER2-positive patients ($p < 0.0001$). CNS metastases diagnosis was based on symptoms in 70.7% of patients, and on systematic imaging in 29.3% of patients (asymptomatic patients). The patients' performance status at the time of CNS metastases diagnosis was available in 1297 patients (32.1%) and distributed as follows: score 0 in 301, score 1 in 615, score 2 in 263, score 3 in 104 and score 4 in 14 patients. With regard to biological subgroups, among patients with CNS metastases 44.9%, 14.4%, 15.0% and 25.6% had an HR+/HER2– HER2+/HR+, HER2+/HR– and triple-negative tumour, respectively.

Risk factors for CNSM occurrence and CNSM-FS (population 1, n = 16,701). In population 1 (n = 16,701), 4118 patients (24.6%) developed CNS metastases. Among them, 1200 (7.2%) had CNS metastases at the time of MBC diagnosis, while 2918 developed them during the course of MBC, with a median time interval of 17.0 months (95% CI: 16.5–17.9) after MBC diagnosis. The proportion of patients with CNS metastases diagnosed at MBC diagnosis or later during the course of MBC is reported in

Table 1. Characteristics of patients selected for the study

| | Population 1 ^a n = 16,701 | Population 2 ^b n = 4033 |
|--|---|---------------------------------------|
| <i>Characteristics at breast cancer diagnosis</i> | | |
| Age at breast cancer diagnosis, median (range), years | 54.7 (19.2–98.5) | 51.6, 20.3–90.5 |
| Gender | | |
| Female | 16 552 (99.1%) | 4 007 (99.4%) |
| Male | 149 (0.9%) | 26 (0.6%) |
| Tumour size | n = 7646 | n = 1969 |
| Tx/T0/Tis | 363 (4.7%) | 100 (5.1%) |
| T1/T2 | 4 229 (55.3%) | 1 044 (53.0%) |
| T3/T4 | 3 054 (39.9%) | 825 (41.9%) |
| Node status | n = 7324 | n = 1901 |
| Nx | 318 (4.3%) | 77 (4.1%) |
| N0 | 3169 (43.3%) | 744 (39.1%) |
| N1/N2/N3 | 3837 (52.4%) | 1080 (56.8%) |
| Metastatic status | n = 16,701 | n = 16,701 |
| M0 | 11,901 (71.3%) | 2974 (73.7%) |
| M1 | 4800 (28.7%) | 1059 (26.3%) |
| Histology | n = 15,584 | n = 3790 |
| Ductal carcinoma | 12 537 (80.4%) | 3 222 (85.0%) |
| Lobular carcinoma | 2 187 (14.0%) | 395 (10.4%) |
| Other | 860 (5.5%) | 173 (4.6%) |
| SBR grade | n = 14,779 | n = 3652 |
| I/II | 8308 (56.2%) | 1641 (44.9%) |
| III | 6471 (43.8%) | 2011 (55.1%) |
| ER status | n = 15,494 | n = 3800 |
| Negative | 3834 (24.7%) | 1506 (39.6%) |
| Positive | 11,660 (75.3%) | 2294 (60.4%) |
| PR status | n = 14,990 | n = 3682 |
| Negative | 6375 (42.5%) | 2075 (56.4%) |
| Positive | 8615 (57.5%) | 1607 (43.6%) |
| HER2 status | n = 13,621 | n = 3488 |
| Negative | 11,090 (81.4%) | 2481 (71.1%) |
| Positive | 2531 (18.6%) | 1007 (28.9%) |
| Tumour biology | n = 13,498 | n = 3453 |
| HER2–/HR+ | 8654 (64.1%) | 1572 (45.5%) |
| HER2+/HR+ | 1480 (11.0%) | 504 (14.6%) |
| HER2–/HR– | 1010 (7.5%) | 490 (14.2%) |
| Triple negative | 2354 (17.4%) | 887 (25.7%) |
| Radiotherapy delivered on the breast | n = 16,654 | n = 4023 |
| Yes | 10,463 (62.8%) | 2668 (66.3%) |
| Systemic treatment | n = 16,657 | n = 4026 |
| Yes | 8498 (51.0%) | 2463 (61.2%) |
| Trastuzumab (HER2+ patients) | n = 2531 | n = 1007 |
| Yes | 947 (37.4%) | 472 (46.9%) |
| Hormone therapy (HR+ patients) | n = 11,947 | n = 2375 |
| Yes | 7354 (61.6%) | 1541 (64.9%) |
| <i>Characteristics at metastatic disease diagnosis</i> | | |
| Age at MBC diagnosis, median (range), years | 61.2 (19.2–99.4) | 56.0 (22.0–91.0) |
| Time interval from breast cancer diagnosis, median (range), months | 35.7 (0.0–657.7) | 27.3 (0.0–591.7) |

Table 1 continued

| | Population 1 ^a n = 16,701 | Population 2 ^b n = 4033 |
|--|---|---------------------------------------|
| Time interval from breast cancer diagnosis | n = 16,656 | n = 4026 |
| < 6 months | 4763 (28.6%) | 1053 (26.2%) |
| 6–24 months | 2185 (13.1%) | 789 (19.6%) |
| ≥ 24 months | 9708 (58.3%) | 2184 (54.2%) |
| ER status ^c | n = 16,100 | n = 3906 |
| Positive | 11,924 (74.1%) | 2292 (58.7%) |
| PR status ^c | n = 15,702 | n = 3815 |
| Positive | 8308 (52.9%) | 1515 (39.7%) |
| HER2 status ^c | n = 14,938 | n = 3707 |
| Positive | 2719 (18.2%) | 1066 (28.8%) |
| Tumour biology | n = 15,004 | n = 3708 |
| HER2–/HR+ | 9533 (63.5%) | 1667 (45.0%) |
| HER2+/HR+ | 1652 (11.0%) | 534 (14.4%) |
| HER2+/HR– | 1168 (7.8%) | 557 (15.0%) |
| Triple negative | 2651 (17.7%) | 950 (25.6%) |
| Number of metastatic sites | | |
| Median (range) | 1 (0–9) | – |
| CNS metastases | n = 16,065 1200 (7.5%) | – |
| Bone metastases | n = 16,067 9512 (59.2%) | – |
| Lung metastases | n = 16,065 4103 (25.3%) | – |
| Liver metastases | n = 16,060 4491 (28.0%) | – |
| Lymph node metastases | n = 16,066 4478 (27.9%) | – |
| Subcutaneous metastases | n = 16,065 1834 (11.4%) | – |
| Pleural metastases | n = 16,067 1789 (11.1%) | – |
| Metastases of other site(s) | n = 16,068 1727 (10.7%) | – |

SBR grade Scarff–Bloom–Richardson grade, ER oestrogen receptor, PR progesterone receptor, HER2 human epidermal growth factor receptor 2, MBC metastatic breast cancer, CNS central nervous system

^aPopulation 1 corresponds to the overall ESME population

^bPopulation 2 corresponds to patients diagnosed with CNS metastases before the closing date of the study analyses (January 15th, 2016)

^cER, PR and HER2 statuses at MBC diagnosis are defined as follows: status at the metastatic disease diagnosis, if available, or status of the primary tumour

Supplementary Table 2. Overall, the CNSM-FS (defined as the time interval between the date of MBC diagnosis and the date of CNS metastasis diagnosis) was 10.8 months (95% CI: 10.2–11.5) among patients who developed CNS metastases. The 6-, 12-, 24- and 48-month CNSM-FS rates were 61.5%, 47.2%, 25.3% and 6.4%, respectively, among patients who developed CNS metastases.

The results of the univariate CNSM-FS analysis are provided in Table 2. Among patients who developed CNS metastases, the molecular subtype (at MBC diagnosis) was significantly associated with CNSM-FS: HER2–/HR+ 15.1 (95% CI: 14.3–16.1), HER2+/HR+ 12.8 (95% CI: 11.5–14.4), HER2+/HR– 8.5 (95% CI: 6.8–9.6) and triple-negative 5.8 months (95% CI: 4.8–6.7) ($p < 0.001$) (Fig. 2).

HER2 positivity and HR, ER and PR negativity were also associated with a shorter CNSM-FS when considered independently (Table 2 and Supplementary Fig. 1).

In multivariate analysis, molecular subtype was independently associated with CNSM-FS: hazard ratios were 2.01 (95% CI: 1.29–3.15, $p = 0.0021$) and 1.57 (95% CI: 1.25–1.97, $p < 0.0001$) for HER2+/HR– and triple-negative tumours, respectively (compared with HER2–/HR+ tumours). A higher histoprognostic grade, longer metastases-free interval (l6–24 [vs. <6 months]), younger age at MBC diagnosis (<50 vs. >70), higher number of metastatic sites at MBC diagnosis (≥3 vs. <3) and having received previous intravenous systemic therapy or radiation therapy were also associated with a shorter CNSM-FS (Table 2).

Prognostic of patients with CNS metastases (population 2, n = 4033). Following CNS metastases diagnosis, 2.3% of patients underwent a neurosurgical resection of the lesions, 10.5% received a stereotactic radiation therapy, 45.2% whole-brain radiation therapy, 59.3% a systemic treatment and 16.2% best supportive care only.

Overall survival. With a 30-month median follow-up (95% CI: 28.0–32.0) after CNS metastases diagnosis (population 2), 2983 patients (74%) had died. Median OS after CNS metastases diagnosis was 7.9 months (95% CI: 7.2–8.4). The 6-, 12-, 24- and 48-month survival rates were 56.3%, 37.7%, 22.1% and 8.0%, respectively.

Median OS was 7.1 months (95% CI: 6.3–7.9) for HER2–/HR+, 18.9 months (95% CI: 15.0–23.0) for HER2+/HR+, 13.1 months (95% CI: 11.7–15.2) for HER2+/HR– and 4.4 months (95% CI: 4–4.8) for triple-negative tumours ($p < 0.0001$).

The results of the univariate analysis of OS are provided in Table 3, Fig. 3 and Supplementary Fig. 2. In multivariable analysis, the molecular subtype was independently associated with OS: compared with HER2–/HR+ tumours, hazard ratios were 0.90 (95% CI: 0.80–1.02, $p < 0.0001$), 0.63 (95% CI: 0.55–0.71, $p < 0.0001$) and 1.87 (95% CI: 1.70–2.06, $p < 0.0001$) for HER2+/HR–, HER2+/RH+ and triple-negative tumours, respectively. An older age, symptomatic CNS metastases, a longer time interval between breast cancer and CNS metastases diagnosis, a higher number of metastatic sites and a higher number of previous chemotherapy lines were also associated with shorter OS (Table 3). Of note, performance status, a known prognostic factor in patients with CNS metastases, was not included in the multivariate model due to a high number of missing data (67.8%). Amongst patients with CNS metastases at initial diagnosis of metastatic disease, patients with isolated CNS metastases showed a longer OS compared with patients diagnosed concomitantly with other metastatic site(s) (hazard ratio 0.86, 95% CI: 0.76–0.99, $p = 0.035$).

Progression-free survival. The median PFS after diagnosis of CNS metastases was 3.3 months (95% CI: 3.1–3.4). The PFS rates at 6, 12, 24 and 48 months were 28.8%, 11.5%, 3.5% and 0.9%, respectively. In multivariable analysis, an older age at CNS metastases diagnosis, a longer time interval between breast cancer and CNS metastases diagnosis, a higher number of metastatic sites and a higher number of previous chemotherapy lines were independently associated with a shorter PFS. The tumour biology also had a significant effect on PFS, triple-negative tumours being associated with a shorter PFS and HER2-positive tumours with a longer PFS (Supplementary Table 3). Among patients with CNS metastases at initial diagnosis of metastatic disease, a longer PFS was reported for patients with isolated CNS metastases compared with those with other metastatic site(s) (hazard ratio 0.88, 95% CI: 0.78–0.99, $p = 0.034$).

CNS–PFS. The median CNS–PFS was 5.5 months (95% CI: 5.2–5.8). The CNS–PFS rates at 6, 12, 24 and 48 months were 47.1%, 26.2%,

Table 2. Univariate and multivariate analyses of CNSM-FS

| Parameter | Univariate analysis | | | Multivariate analysis <i>n</i> = 11,313 | |
|--|-----------------------|-------------------------|-----------------|--|-------------------|
| | Hazard ratio (95% CI) | Median CNSM-FS (months) | <i>P</i> -value | Hazard ratio (95% CI) | <i>P</i> -value |
| <i>SBR grade</i> | | | <0.0001 | | <0.0001 |
| I/II | 1 | NR (90.8–NR) | | 1 | |
| III | 1.96 (1.84–2.10) | 52.9 (48.7–57.7) | | 1.27 (1.18–1.38) | |
| <i>Histological subtype</i> | | | <0.0001 | | |
| Ductal carcinoma | 1 | 77.8 (73.3–90.8) | | | |
| Lobular carcinoma | 0.67 (0.60–0.74) | NR (78.2–NR) | | | |
| Other | 0.84 (0.72–0.98) | NR (NR–NR) | | | |
| <i>Age at MBC diagnosis</i> | | | <0.0001 | | <0.0001 |
| <50 | 1 | 59.6 (55.5–66.7) | | 1 | |
| 50–70 | 0.76 (0.71–0.82) | 76.5 (73.3–85.9) | | 0.94 (0.87–1.02) | |
| >70 | 0.43 (0.39–0.48) | NR (NR–NR) | | 0.66 (0.59–0.75) | |
| <i>MFI (months)</i> | | | <0.0001 | | <0.0001 |
| <6 | 1 | 83.3 (73.7–NR) | | 1 | |
| 6–24 | 2.57 (2.35–2.83) | 33.5 (29.1–41.1) | | 1.44 (1.20–1.73) | |
| ≥24 | 1.00 (0.93–1.08) | 91.1 (86.0–NR) | | 0.96 (0.80–1.15) | |
| <i>Number of metastatic sites at MBC diagnosis</i> | | | <0.0001 | | <0.0001 |
| <3 | 1 | NE (86.0–NE) | | 1 | |
| ≥3 | 2.14 (2.00–2.29) | 53.8 (47.9–61.1) | | 2.16 (1.99–2.34) | |
| <i>Tumour biology^a</i> | | | <0.0001 | | <0.0001 |
| HER2–/HR+ | 1 | NR (91.1–NR) | | 1 | |
| HER2+/HR+ | 2.01 (1.83–2.22) | 61.7 (51.7–74.1) | | 1.33 (0.89–1.99) | |
| HER2+/HR– | 3.69 (3.35–4.06) | 24.9 (22.7–28.9) | | 2.01 (1.29–3.15) | |
| Triple negative | 3.45 (3.18–3.75) | 29.9 (27.0–33.1) | | 1.57 (1.25–1.97) | |
| <i>HER2 status^a</i> | | | <0.0001 | | |
| Negative | 1 | NR (85.9–NR) | | | |
| Positive | 1.93 (1.80–2.07) | 40.8 (37.3–47.5) | | | |
| <i>ER status^a</i> | | | <0.0001 | | |
| Positive | 1 | NR (90.8–NR) | | | |
| Negative | 3.07 (2.88–3.28) | 29.0 (26.3–32.5) | | | |
| <i>PR status^a</i> | | | <0.0001 | | |
| Positive | 1 | NR (91.1–NR) | | | |
| Negative | 2.20 (2.06–2.34) | 53.8 (47.9–61.1) | | | |
| <i>HR status^a</i> | | | <0.0001 | | |
| Positive | 1 | NE (90.8–NE) | | | |
| Negative | 3.19 (2.98–3.41) | 27.0 (23.6–29.5) | | | |
| <i>Previous systemic treatment (per os)</i> | | | <0.0001 | | |
| No | 1 | 86.0 (80.7–NR) | | | |
| Yes | 1.63(1.35–1.97) | 71.4 (67.5–78.6) | | | |
| <i>Previous systemic treatment (IV)</i> | | | <0.0001 | | 0.0020 |
| No | 1 | NR (86.0–NR) | | 1 | |
| Yes | 1.65 (1.54–1.75) | 71.4 (67.5–78.6) | | 1.22 (1.08–1.39) | |
| <i>Previous radiation therapy</i> | | | <0.0001 | | 0.0119 |
| No | 1 | 85.7 (75.6–NR) | | 1 | |
| Yes | 1.20 (1.13–1.29) | 85.9 (77.8–NR) | | 1.22 (1.04–1.42) | |

CNSM-FS central nervous system metastases-free survival, ER oestrogen receptor, HER2 human epidermal growth factor receptor 2, IV intravenous, MFI metastases-free interval, NR not reached, PR progesterone receptor, SBR grade Scarff–Bloom–Richardson grade

^aAt MBC diagnosis, statuses defined as follows: status at the metastatic disease diagnosis, if available, or status of the primary tumour,

Bold values indicate statistical significance *p* < 0.05




Fig. 2 CNSM-FS according to the tumour biology

11.5% and 3.6%, respectively. In multivariable analysis, factors independently associated with a shorter CNS-PFS were the same as for PFS. As for PFS, triple-negative tumours were associated with a shorter CNS-PFS (Supplementary Table 4). The CNS-PFS was not significantly associated with de novo diagnosis compared with relapsed MBC (median PFS: 6.1 months and 5.3 months, respectively, $p = 0.052$).

Subgroup of patients with HER2-positive tumours

Among the 2 531 patients (from population 1) with a HER2-positive tumour, 1027 developed CNS metastases. The incidence rate of CNS metastases was 16.6% in patients with de novo MBC ($n = 1044$, 41.2%) and 27.2% in patients with relapse MBC ($n = 1487$, 58.7%). Amongst the 1027 patients with CNS metastases, the median CNSM-FS of 38.3 months (95% CI: 34.0–43.2) (median time interval among the 1027 patients with CNS metastases: 10.2 months, 95% CI: 9.0–11.4). In multivariable analysis, an older age at CNS metastases diagnosis, a longer time interval between breast cancer diagnosis and MBC, a higher number of metastatic sites, HR negativity and the administration of a previous HER2-targeted therapy were independently associated with a shorter CNSM-FS (Supplementary Table 5).

After a median follow-up of 29.9 months (95% CI: 27.6–33.0) after CNS metastasis diagnosis, 649 patients (64.5%) had died. The median OS was 15.2 months (95% CI: 13.5–17.4), and survival rates at 6, 12, 24 and 48 months were 73.9%, 57.1%, 36.4% and 13.6%, respectively.

In multivariable analysis, we found that an older age, HR negativity, a higher number of metastatic sites, a higher number of previous chemotherapy lines and no administration of a previous HER2-targeted therapy were prognostic factors associated with a shorter OS (Supplementary Table 6).

DISCUSSION

We show, in a large multicentre real-world database of MBC patients, that breast cancer molecular subtype strongly impacts the occurrence, kinetics and prognosis of CNS metastases.

Only few data are available regarding prevalence and incidence rates of CNS metastases in breast cancer patients, as, to our knowledge, no nationwide reporting system for breast cancer patients diagnosed with CNS metastases exists. The data come from autopsy studies and population-based studies with various methodologies. Our analysis of the EMSE MBC database provides an estimate of the cumulated incidence rate of CNS metastases among MBC patients of 24.6%. At the time of metastatic disease diagnosis, 7.2% of patients were diagnosed with CNS metastases (12.3% in patients with HER2+ tumours). In a population-based study from the “Surveillance, Epidemiology and End Results” (SEER) database, 614/7575 patients (8.1%) with de novo MBC were diagnosed with BM at MBC diagnosis (105 with isolated BM and 509 with other metastatic sites).³¹ In a prospective cohort study from the “National Comprehensive Cancer Network” (NCCN) including 3394 HER2+ patients, BM was present at the first recurrence in 20 and 13% of patients with a HER2+/HR– and a HER2+/RH+ tumours, respectively.³²

We found an overrepresentation of HER2-positive, HR-negative and triple-negative tumours among MBC patients diagnosed with CNS metastases, suggesting that tumour biology impacts the risk of CNS involvement in breast cancer. Indeed, an increased risk of BM was reported in previous studies for HER2-positive^{11,20,33,34} and HR-negative^{17,19,21,22,35–37} patients. In our study, the cumulated incidence rate of CNS metastases was 21.8% in HER2-positive tumours (compared with 11.1% in HER2-negative tumours), 32.5% in HR-negative tumours (compared with 9.2% in HR-positive tumours) and 32.7% in triple-negative tumours, respectively, consistent with previous literature data.^{37–39} HER2-positive, HR-negative and triple-negative tumours were reported respectively in 29.4%, 40.6% and 25.6% of patients with CNS metastases. This compares with 18.8%, 25.5% and 17.7% of patients in the whole ESME database and with 16.6%, 26.4% and 19.5% in a series of 11 011 unselected stage I–III breast cancer patients.⁴⁰ These proportions in patients with CNS metastases are consistent with previous data for HR-negative^{19,35,36,41,42} and triple-negative tumours,^{15,21,41,42} but not for HER2-positive tumours. Indeed, previous reports have described higher proportions (34.8–43.1%)

Table 3. Prognostic factors of OS in patients diagnosed with CNS metastases

| Parameter | Univariate analysis | | | Multivariate analysis n = 3496 | |
|--|-----------------------|--------------------|---------|-----------------------------------|-------------------|
| | Hazard ratio (95% CI) | Median OS (months) | P-value | Hazard ratio (95% CI) | P-value |
| <i>Age at CNSM diagnosis</i> | | | <0.0001 | | <0.0001 |
| <50 | 1 | 10.5 (9.4–12.0) | | 1 | |
| 50–70 | 1.18 (1.09–1.28) | 7.5 (6.9–8.5) | | 1.20 (1.09–1.31) | |
| >70 | 1.60 (1.43–1.79) | 4.5 (4.0–5.3) | | 1.72 (1.52–1.94) | |
| <i>Performance status at CNSM diagnosis</i> | | | | | |
| 0 | 1 | 18.5 (14.7–22.1) | | | |
| 1 | 1.48 (1.23–1.79) | 9.5 (7.9–11.6) | | | |
| 2 | 1.80 (1.44–2.24) | 5.4 (4.0–8.8) | | | |
| 3 | 3.40 (2.57–4.51) | 2.7 (2.0–3.7) | | | |
| 4 | 2.65 (1.35–5.21) | 5.1 (2.2–14.2) | | | |
| <i>Symptoms at CNSM diagnosis</i> | | | <0.0001 | | 0.0001 |
| Present | 1 | 7.4 (6.8–8.0) | | 1 | |
| Absent | 0.81 (0.75–0.88) | 10.1 (9.0–11.7) | | 0.84 (0.77–0.92) | |
| <i>Time interval between breast cancer and CNSM diagnosis (months)</i> | | | <0.0001 | | 0.0002 |
| <9 | 1 | 9.4 (8.3–10.1) | | 1 | - |
| 9–18 | 1.29 (1.18–1.42) | 6.7 (6.0–8.3) | | 1.08 (0.97–1.21) | |
| ≥18 | 1.31 (1.21–1.43) | 6.3 (5.6–7.2) | | 0.84 (0.75–0.95) | |
| <i>Tumour biology^a</i> | | | <0.0001 | | <0.0001 |
| HER2–/HR+ | 1 | 7.1 (6.3–7.9) | | 1 | - |
| HER2+/HR+ | 0.57 (0.50–0.64) | 18.9 (15.0–23.0) | | 0.63 (0.55–0.72) | <0.0001 |
| HER2+/HR– | 0.72 (0.65–0.81) | 13.1 (11.7–15.2) | | 0.86 (0.77–0.97) | <0.0001 |
| Triple negative | 1.55 (1.42–1.69) | 4.4 (4.0–4.8) | | 1.88 (1.71–2.07) | <0.0001 |
| <i>HER2 status^a</i> | | | <0.0001 | | |
| Positive | 1 | 15.1 (13.5–17.3) | | | |
| Negative | 1.81 (1.66–1.97) | 5.7 (5.3–6.2) | | | |
| <i>ER status^a</i> | | | <0.0001 | | |
| Positive | 1 | 9.1 (8.1–9.8) | | | |
| Negative | 1.28 (1.19–1.38) | 6.4 (5.9–7.1) | | | |
| <i>PR status^a</i> | | | <0.0001 | | |
| Positive | 1 | 8.5 (7.7–9.5) | | | |
| Negative | 1.17 (1.08–1.26) | 7.1 (6.5–7.9) | | | |
| <i>HR status^a</i> | | | <0.0001 | | |
| Positive | 1 | 9.0 (8.1–9.8) | | | |
| Negative | 1.30 (1.20–1.40) | 6.4 (5.8–7.0) | | | |
| <i>Number of metastatic sites</i> | | | <0.0001 | | <0.0001 |
| <3 | 1 | 12.1 (10.8–13.1) | | 1 | |
| ≥3 | 1.52 (1.41–1.65) | 6.0 (5.6–6.5) | | 1.46 (1.34–1.60) | |
| <i>Number of previous chemotherapy lines</i> | | | <0.0001 | | <0.0001 |
| <3 | 1 | 10.0 (9.4–10.7) | | 1 | - |
| ≥3 | 1.91 (1.76–2.08) | 4.3 (3.9–4.8) | | 2.01 (1.79–2.27) | <0.0001 |

OS overall survival, CNS central nervous system, CNSM CNS metastases, ER oestrogen receptor, PR progesterone receptor, HER2 human epidermal growth factor receptor 2

^aAt MBC diagnosis, statuses defined as follows: status at the metastatic disease diagnosis, if available, or status of the primary tumour

Bold values indicate statistical significance p < 0.05

of HER2-positive tumours amongst patients with BM.^{21,41,42} In our study, patients were included more recently, and HER2-targeted therapies might have been used more often in the early and metastatic phase of the disease. This could have led to a selection bias favouring HER2-negative tumours among patients with CNS metastases. However, this hypothesis must be considered with caution, as some studies have reported an increased risk of BM in

patients treated with trastuzumab during the adjuvant or metastatic phase.^{5,43,44} If confirmed, this could explain our finding of an increased incidence rate of CNS metastases in patients with relapsed MBC (27.2%) compared with patients with de novo MBC (16.6%). Yet, the impact of previous treatment with trastuzumab on the risk of CNS metastases occurrence is debated, as these results were not reproduced in other studies.^{12,34,45} Of note, the




Fig. 3 OS after CNS metastases diagnosis according to the tumour biology

fact that most patients with CNS metastases have a HER2−/HR+ tumour (45.3%) despite an increased risk of CNS metastases in patients with a HER2-positive and/or a HR-negative tumour is linked with the fact that the incidence of HER2−/HR+ tumours is higher.

In our study, the median time interval between MBC diagnosis and the occurrence of CNS metastases was 10.8 months amongst patients who developed CNS metastases, compared with 10–19 months in previous studies.^{12,21,39} Because patients with CNS metastases occurring after the closing date of study analysis, lost to follow-up or dead without CNS metastases were censored at the closing date of analysis, this time interval is quite prolonged as compared with reported survivals of MBC patients (37.2 months in the ESME MBC database³⁰), suggesting an increased risk of CNS metastases in long MBC survivors (consistently with clinical observation in daily practice). We confirmed a significant impact of tumour biology, HER2 positivity and HR negativity associated with a shorter CNSM-FS.^{12,21,34} These patients at high risk of CNS metastases could potentially benefit from screening strategies, as CNS metastases can be asymptomatic, in order to improve the patients' outcomes by allowing localised BM treatments in a higher proportion of patients.² Indeed, surgery and radiosurgery are yet the only locoregional treatments with a significant positive impact on survival.^{9,10} Prospective studies in this selected population of patients should evaluate the prognostic impact of such strategy. In patients with a HER2-positive tumour, our results show a negative impact of HR negativity on CNSM-FS and on survival following CNS metastases. This result confirms previous data showing a higher risk of CNS metastases³⁴ and a shorter time interval to CNS involvement¹² in patients with a HR−/HER2+ tumour compared with HR+/HER2+ patients. Moreover, we found that patients previously treated with a HER2-targeted therapy had a shorter CNSM-FS compared with those who did not receive such treatment. Previous studies have reported an increased risk of BM in patients treated with trastuzumab during the adjuvant or metastatic phase^{5,43,45} This could be due to an increase control of the systemic disease by trastuzumab, resulting in an improved “systemic” survival while CNS involvement is not prevented because of the low penetration of

trastuzumab in the brain. Further studies are warranted to better clarify these hypotheses.^{12,34,46} Moreover, it must be noted that once the BM has occurred, a number of studies have demonstrated a clinical efficacy of systemic treatment including HER2-targeted therapies.^{47,48}

The prognosis of patients with CNS metastases is poor. In our study, the median OS after the CNS metastasis diagnosis was 7.9 months, lower than that reported in previous breast cancer-related BM series (median OS around 14 months^{19,24}), possibly linked to differences in the inclusion criteria (in the Sperduto's study, only patients referred for radiation therapy were included, whereas this database includes all patients with BM, whatever the treatment modalities). Another important difference is the fact that we included patients with both BM and LM. Indeed, while 4–16-month survivals have been reported in patients with BM,²⁴ survival is <5 months in patients with LM.^{7,22,46} Our results confirmed that survival differs significantly according to the tumour biology, HR-negative, HER2-negative or triple-negative tumours being classically associated with poorer survival.^{19,21,39,41,46,49,50} These biological features have been included in the modified-Breast Graded Prognostic Assessment (GPA) score that aims at predicting survival of MBC patients with BM.⁵¹ In patients with a HER2-positive tumour, our study shows that OS after CNS metastasis diagnosis is negatively impacted by HR negativity. This is consistent with the results of the study based on the SEER data published by Kim et al.: the median OS was 10 months in patients with a HER2+/HR− tumour compared with 23 months in those with a HER2+/HR+ tumour.⁴⁹

We report that a low proportion of patients treated with surgery (2.3%) or stereotactic radiation therapy (10.5%) following CNS metastases should be investigated further in another study.

Our study has some limitations. First, because the database was not specifically designed to study CNS metastases, it was not possible to distinguish intraparenchymal BM from LM. Second, because of unavailable data, some parameters could not be included in the multiparameter analysis of OS despite their demonstrated prognostic value. Indeed, for example, the number

of BM was not described in the ESME MBC database, while it was shown to be prognostic in these patients. Also, it must be acknowledged that the proportion of patients diagnosed with CNS metastases depends on the duration of the patients' follow-up. This could cause a bias for patients who are still alive at the time of the study analysis (representing 45.1% of patients), as it is possible that these patients have or will be diagnosed with CNS metastases after this date. Finally, the results of our survival analyses must be considered with caution, in particular regarding the prognostic value of parameters describing the initial diagnosis, as our population is only composed of metastatic patients.

In conclusion, in this large multicentre real-life study including more than 16,000 MBC patients and over 4000 patients with CNS metastases, we found that the breast cancer molecular subtype strongly impacts the occurrence and kinetics of CNS metastases and the patients' prognosis. HR-negative, HER2-positive and triple-negative tumours are overrepresented in patients developing CNS metastases, supporting a higher risk of CNS metastases in these biological subtypes. Thus, patients with HR-negative and/or HER2-positive tumours could represent a population of choice for clinical trials evaluating treatment strategies for CNS metastases, as well as screening or preventive approaches.

ACKNOWLEDGEMENTS

We would like to thank Dr. Hélène de Forges (Montpellier Cancer Institute) for editing the paper. We thank the 18 French Comprehensive Cancer Centers for providing the data and each ESME local coordinator for managing the project at the local level. Moreover, we thank the ESME Scientific Committee members for their ongoing support. *ESME central coordinating staff:* Head of Research and Development: Claire Labreuveux. Program director: Mathieu Robain. Data Management team: Coralie Courtinard, Emilie Nguyen, Olivier Payen, Irwin Piot, Dominique Schwob and Olivier Villacroux. Operational team: Michaël Chevrot, Daniel Couch, Patricia D'Agostino, Pascale Danglot, Tahar Guesmia, Christine Hamonou, Gaëtane Simon and Julie Tort. Supporting clinical research associates: Elodie Kupfer and Toihiri Said. Project Associate: Nathalie Bouyer. Management assistant: Esméralda Pereira. Software designers: Matou Diop, Blaise Fulpin, José Paredes and Alexandre Vanni. *ESME local coordinators:* Patrick Arveux, Thomas Bachelot, Delphine Berchery, Etienne Brain, Mathias Breton, Loïc Campion, Emmanuel Chamorey, Valérie Dejean, Stéphanie Delaine, Anne-Valérie Guizard, Anne Jaffré, Lilian Laborde, Carine Laurent, Marie-Paule Lebitasy, Agnès Loeb, Muriel Mons, Damien Parent, Geneviève Perrocheau, Marie-Ange Mouret-Reynier, Michel Velten.

AUTHOR CONTRIBUTIONS

Conception of the study (A.D., G.L., W.J., D.P. and T.B.); identification of the population of patients to be included (A.D., J.F., M.R. and M.C.); patients inclusion in the ESME database (G.L., W.J., E.B., M.D., M.A.M.R., A.G., F.D., S.D., M.C., P.A., J.M.F., C.L., J.D.F., I.L., P.C., T.P., L.U., C.J., M.L., V.D., D.P., T.B.); statistical analysis (A.D., J.F. and W.J.); analysis and interpretation of the results (A.D., G.L., J.F., W.J., D.P., T.B. and S.D.); writing of the first draft of the paper (A.D., J.F., G.L., W.J., D.P., T.B. and S.D.); review of the paper and approval of the final version of the paper (A.D., G.L., J.F., W.J., E.B., M.D., M.A.M.R., A.G., F.D., S.D., M.C., P.A., J.M.F., C.L., J.D.F., I.L., P.C., T.P., L.U., C.J., M.L., V.D., M.R., M.C., D.P. and T.B.).

ADDITIONAL INFORMATION

Supplementary information is available for this paper at <https://doi.org/10.1038/s41416-019-0619-y>.

Competing interests: The authors declare no competing interests.

Ethics approval and consent to participate: The ESME MBC database was approved by an independent Ethics Committee (Comité De Protection des Personnes Sud-Est II-2015-79). No formal dedicated informed consent was required, but all patients had approved the use of their electronically recorded data. In compliance with the French regulations, the ESME MBC database was authorised by the French data protection authority (authorisation no. 1704113).

Funding: This work was supported by R&D UNICANCER. The ESME MBC database receives financial support from an industrial consortium (Roche, Pfizer, AstraZeneca,

MSD, Eisai and Daiichi Sankyo). Data collection, analysis and publication is managed entirely by R&D UNICANCER independently of the industrial consortium.

Consent to publish: Not applicable.

Data availability: The analysis data set will be made available upon request.

Note: This work is published under the standard license to publish agreement. After 12 months the work will become freely available and the license terms will switch to a Creative Commons Attribution 4.0 International (CC BY 4.0).

Publisher's note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

REFERENCES

- Lin, N. U., Gaspar, L. E. & Soffietti, R. Breast cancer in the central nervous system: multidisciplinary considerations and management. *Am. Soc. Clin. Oncol. Educ. Book* **37**, 45–56 (2017).
- Miller, K. D., Weathers, T., Haney, L. G., Timmerman, R., Dickler, M., Shen, J. et al. Occult central nervous system involvement in patients with metastatic breast cancer: prevalence, predictive factors and impact on overall survival. *Ann. Oncol.* **14**, 1072–1077 (2003).
- Niwirska, A., Tacikowska, M. & Pieńkowski, T. Occult brain metastases in HER2-positive breast cancer patients: frequency and response to radiotherapy. *Acta Oncol.* **46**, 1027–1029 (2007).
- Tsakada, Y., Fouad, A., Pickren, J. & Lane, W. Central nervous system metastasis from breast carcinoma. *Autopsy Study Cancer* **52**, 2349–2354 (1983).
- Lin, N. U. & Winer, E. P. Brain metastases: the HER2 paradigm. *Clin. Cancer Res.* **13**, 1648–1655 (2007).
- Pestalozzi, B. C. Brain metastases and subtypes of breast cancer. *Ann Oncol.* **20**, 803–805 (2009).
- Le Rhun, E., Weller, M., Brandsma, D., Van den Bent, M., de Azambuja, E., Henriksson, R. et al. EANO-ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up of patients with leptomeningeal metastasis from solid tumours. *Ann Oncol.* **28**, iv84–99 (2017). (suppl_4).
- Fox, B. D., Cheung, V. J., Patel, A. J., Suki, D. & Rao, G. Epidemiology of metastatic brain tumors. *Neurosurg. Clin. N. Am.* **22**, 1–6 (2011).
- Andrews, D. W., Scott, C. B., Sperduto, P. W., Flanders, A. E., Gaspar, L. E., Schell, M. C. et al. Whole brain radiation therapy with or without stereotactic radiosurgery boost for patients with one to three brain metastases: phase III results of the RTOG 9508 randomised trial. *Lancet.* **363**, 1665–1672 (2004).
- Tsao, M. N., Rades, D., Wirth, A., Lo, S. S., Danielson, B. L., Gaspar, L. E. et al. Radiotherapeutic and surgical management for newly diagnosed brain metastasis(es): an American Society for Radiation Oncology evidence-based guideline. *Pract. Radiat. Oncol.* **2**, 210–225 (2012).
- Kennecke, H., Yerushalmi, R., Woods, R., Cheang, M. C. U., Voduc, D., Speers, C. H. et al. Metastatic behavior of breast cancer subtypes. *J. Clin. Oncol.* **28**, 3271–3277 (2010).
- Berghoff, A., Bago-Horvath, Z., De Vries, C., Dubsy, P., Pluschnig, U., Rudas, M. et al. Brain metastases free survival differs between breast cancer subtypes. *Br. J. Cancer* **106**, 440–446 (2012).
- Pestalozzi, B. C., Zahrieh, D., Price, K. N., Holmberg, S. B., Lindtner, J., Collins, J. et al. Identifying breast cancer patients at risk for Central Nervous System (CNS) metastases in trials of the International Breast Cancer Study Group (IBCSG). *Ann Oncol.* **17**, 935–944 (2006).
- Sørli, T., Perou, C. M., Tibshirani, R., Aas, T., Geisler, S., Johnsen, H. et al. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. *Proc. Natl Acad. Sci. USA* **98**, 10869–10874 (2001).
- Heitz, F., Harter, P., Lueck, H.-J., Fissler-Eckhoff, A., Lorenz-Salehi, F., Scheil-Bertram, S. et al. Triple-negative and HER2-overexpressing breast cancers exhibit an elevated risk and an earlier occurrence of cerebral metastases. *Eur. J. Cancer* **45**, 2792–2798 (2009).
- Kaplan, M. A., Isikdogan, A., Koca, D., Kucukoner, M., Gumusay, O., Yildiz, R. et al. Biological subtypes and survival outcomes in breast cancer patients with brain metastases (study of the Anatolian Society of Medical Oncology). *Oncology* **83**, 141–150 (2012).
- Slimane, K., Andre, F., Delalogue, S., Dunant, A., Perez, A., Grenier, J. et al. Risk factors for brain relapse in patients with metastatic breast cancer. *Ann Oncol.* **15**, 1640–1644 (2004).
- Rudat, V., El-Sweilmeen, H., Brune-Erber, I., Nour, A. A., Almasri, N., Altuwajri, S. et al. Identification of breast cancer patients with a high risk of developing brain metastases: a single-institutional retrospective analysis. *BMC Cancer* **14**, 289 (2014).

19. Shen, Q., Sahin, A. A., Hess, K. R., Suki, D., Aldape, K. D., Sawaya, R. et al. Breast cancer with brain metastases: clinicopathologic features, survival, and paired biomarker analysis. *Oncologist* **20**, 466–473 (2015).
20. Sanna, G., Franceschelli, L., Rotmensz, N., Botteri, E., Adamoli, L., Marengi, C. et al. Brain metastases in patients with advanced breast cancer. *Anticancer Res.* **27**, 2865–2869 (2007). (4C).
21. Darlix, A., Griguolo, G., Thezenas, S., Kantelhardt, E., Thomssen, C., Dieci, M. V. et al. Hormone receptors status: a strong determinant of the kinetics of brain metastases occurrence compared with HER2 status in breast cancer. *J. Neurooncol.* **138**, 369–382 (2018).
22. Griguolo, G., Jacot, W., Kantelhardt, E., Dieci, M. V., Bourgier, C., Thomssen, C. et al. External validation of modified breast graded prognostic assessment for breast cancer patients with brain metastases: a multicentric European experience. *Breast* **37**, 36–41 (2018).
23. Lin, N. U., Bellon, J. R. & Winer, E. P. CNS metastases in breast cancer. *J. Clin. Oncol.* **22**, 3608–3617 (2004).
24. Sperduto, P. W., Kased, N., Roberge, D., Xu, Z., Shanley, R., Luo, X. et al. Effect of tumor subtype on survival and the graded prognostic assessment for patients with breast cancer and brain metastases. *Int. J. Radiat. Oncol. Biol. Phys.* **82**, 2111–2117 (2012).
25. Gauthier, H., Guilhaume, M. N., Bidard, F. C., Pierga, J. Y., Girre, V., Cottu, P. H. et al. Survival of breast cancer patients with meningeal carcinomatosis. *Ann Oncol.* **21**, 2183–2187 (2010).
26. Griguolo, G., Poudroux, S., Dieci, M. V., Jacot, W., Bourgier, C., Miglietta, F. et al. Clinicopathological and treatment-associated prognostic factors in patients with breast cancer leptomeningeal metastases in relation to tumor biology. *Oncologist* **23**, 1289–1299 (2018).
27. Lara-Medina, F., Crismatt, A., Villarreal-Garza, C., Alvarado-Miranda, A., Flores-Hernández, L., González-Pinedo, M. et al. Clinical features and prognostic factors in patients with carcinomatous meningitis secondary to breast cancer. *Breast J.* **18**, 233–241 (2012).
28. Braccini, A.-L., David, A., Simon, T., Gilles, R., Jean-Marc, F. & William, J. Comparative performances of prognostic indexes for breast cancer patients presenting with brain metastases. *BMC Cancer* **13**, 70 (2013).
29. Delaloge, S., Pérol, D., Courtinard, C., Brain, E., Asselain, B., Bachelot, T. et al. Paclitaxel plus bevacizumab or paclitaxel as first-line treatment for HER2-negative metastatic breast cancer in a multicenter national observational study. *Ann Oncol.* **27**, 1725–1732 (2016).
30. Gobbi, E., Ezzalfani, M., Dieras, V., Bachelot, T., Brain, E., Debled, M. et al. Time trends of overall survival among metastatic breast cancer patients in the real-life ESME cohort. *Eur. J. Cancer* **96**, 17–24 (2018).
31. Wu, S.-G., Li, H., Tang, L.-Y., Sun, J.-Y., Zhang, W.-W., Li, F.-Y. et al. The effect of distant metastases sites on survival in de novo stage-IV breast cancer: a SEER database analysis. *Tumour Biol.* **39**, 1010428317705082 (2017).
32. Vaz-Luis, I., Ottesen, R. A., Hughes, M. E., Marcom, P. K., Moy, B., Rugo, H. S. et al. Impact of hormone receptor status on patterns of recurrence and clinical outcomes among patients with human epidermal growth factor-2-positive breast cancer in the National Comprehensive Cancer Network: a prospective cohort study. *Breast Cancer Res.* **14**, R129 (2012).
33. Leyland-Jones, B. Human epidermal growth factor receptor 2-positive breast cancer and central nervous system metastases. *J. Clin. Oncol.* **27**, 5278–5286 (2009).
34. Brufsky, A. M., Mayer, M., Rugo, H. S., Kaufman, P. A., Tan-Chiu, E., Tripathy, D. et al. Central nervous system metastases in patients with HER2-positive metastatic breast cancer: incidence, treatment, and survival in patients from registHER. *Clin. Cancer Res.* **17**, 4834–4843 (2011).
35. Martin, A. M., Cagney, D. N., Catalano, P. J., Warren, L. E., Bellon, J. R., Punglia, R. S. et al. Brain metastases in newly diagnosed breast cancer: a population-based study. *JAMA Oncol.* **3**, 1069–1077 (2017).
36. Matsuo, S., Watanabe, J., Mitsuya, K., Hayashi, N., Nakasu, Y. & Hayashi, M. Brain metastasis in patients with metastatic breast cancer in the real world: a single-institution, retrospective review of 12-year follow-up. *Breast Cancer Res. Treat* **162**, 169–179 (2017).
37. Buonomo, O. C., Caredda, E., Portarena, I., Vanni, G., Orlandi, A., Bagni, C. et al. New insights into the metastatic behavior after breast cancer surgery, according to well-established clinicopathological variables and molecular subtypes. *PLoS ONE* **12**, e0184680 (2017).
38. Gabos, Z., Sinha, R., Hanson, J., Chauhan, N., Hugh, J., Mackey, J. R. et al. Prognostic significance of human epidermal growth factor receptor positivity for the development of brain metastasis after newly diagnosed breast cancer. *J. Clin. Oncol.* **24**, 5658–5663 (2006).
39. Jin, J., Gao, Y., Zhang, J., Wang, L., Wang, B., Cao, J. et al. Incidence, pattern and prognosis of brain metastases in patients with metastatic triple negative breast cancer. *BMC Cancer* **18**, 446 (2018).
40. Hess, K. R. & Esteva, F. J. Effect of HER2 status on distant recurrence in early stage breast cancer. *Breast Cancer Res. Treat* **137**, 449–455 (2013).
41. Niikura, N., Hayashi, N., Masuda, N., Takashima, S., Nakamura, R., Watanabe, K., Widhalm, G. et al. Descriptive statistical analysis of a real life cohort of 2419 patients with brain metastases of solid cancers. *ESMO Open* **1**, e000024 (2016).
42. Bendell, J. C., Domchek, S. M., Burstein, H. J., Harris, L., Younger, J., Kuter, I. et al. Treatment outcomes and prognostic factors for patients with brain metastases from breast cancer of each subtype: a multicenter retrospective analysis. *Breast Cancer Res. Treat* **147**, 103–112 (2014).
43. Berghoff, A. S., Schur, S., Füreder, L. M., Gatterbauer, B., Dieckmann, K., Widhalm, G. et al. Descriptive statistical analysis of a real life cohort of 2419 patients with brain metastases of solid cancers. *ESMO Open* **1**, e000024 (2016).
44. Bria, E., Cuppone, F., Fornier, M., Nisticò, C., Carlini, P., Milella, M. et al. Cardio-toxicity and incidence of brain metastases after adjuvant trastuzumab for early breast cancer: the dark side of the moon? A meta-analysis of the randomized trials. *Breast Cancer Res. Treat* **109**, 231–239 (2008).
45. Pestalozzi, B. C., Holmes, E., de Azambuja, E., Metzger-Filho, O., Hogge, L., Scullion, M. et al. CNS relapses in patients with HER2-positive early breast cancer who have and have not received adjuvant trastuzumab: a retrospective substudy of the HERA trial (BIG 1-01). *Lancet Oncol.* **14**, 244–248 (2013).
46. Morikawa, A., Jordan, L., Rozner, R., Patil, S., Boire, A., Pentsova, E. et al. Characteristics and outcomes of patients with breast cancer with leptomeningeal metastasis. *Clin. Breast Cancer* **17**, 23–28 (2017).
47. Bachelot, T., Romieu, G., Campone, M., Diéras, V., Cropet, C., Dalenc, F. et al. Lapatinib plus capecitabine in patients with previously untreated brain metastases from HER2-positive metastatic breast cancer (LANDSCAPE): a single-group phase 2 study. *Lancet Oncol.* **14**, 64–71 (2013).
48. Jacot, W., Pons, E., Frenel, J.-S., Guiu, S., Levy, C., Heudel, P. E. et al. Efficacy and safety of trastuzumab emtansine (T-DM1) in patients with HER2-positive breast cancer with brain metastases. *Breast Cancer Res. Treat* **157**, 307–318 (2016).
49. Kim, Y.-J., Kim, J.-S. & Kim, I. A. Molecular subtype predicts incidence and prognosis of brain metastasis from breast cancer in SEER database. *J. Cancer Res. Clin. Oncol.* **144**, 1803–1816 (2018).
50. Eichler, A. F., Kuter, I., Ryan, P., Schapira, L., Younger, J. & Henson, J. W. Survival in patients with brain metastases from breast cancer: the importance of HER-2 status. *Cancer* **112**, 2359–2367 (2008).
51. Subbiah, I. M., Lei, X., Weinberg, J. S., Sulman, E. P., Chavez-MacGregor, M., Tripathy, D. et al. Validation and development of a modified breast graded prognostic assessment as a tool for survival in patients with breast cancer and brain metastases. *J. Clin. Oncol.* **33**, 2239–2245 (2015).